JAMP Pharma Group announced the launch of two biosimilar products in oncology, PrPexegra® and PrFilra®. PrPexegra® is a biosimilar alternative to the reference product PrNeulasta® and PrFilra® is a biosimilar alternative to the reference product PrNeupogen® both commercialized in Canada by Amgen Canada.
PrPexegra® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
PrFilra® is indicated for reducing the frequency of infections manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic agents, and in patients with severe congenital, idiopathic, or cyclic neutropenia.
These two launches will expand the range of treatment options for patients. PrPexegra® and PrFilra® are among the biosimilars of pegfilgrastim and filgrastim, respectively, that are currently authorized for sale in Canada by a Canadian-owned company. As a result, JAMP Pharma Group is committed to improving access to affordable care for Canadian patients.
"We are extremely proud to add PrPexegra® and PrFilra® to our growing biosimilars portfolio. This marks the first oncology biosimilar products for our BioJAMP® division", said Louis Pilon, President and CEO of the JAMP Pharma Group. "These launches align with our mission to provide diverse therapeutic solutions to Canadian patients and are a testament to our expertise in biosimilars."
PrPexegra® is currently authorized for sale by Health Canada as a preservative-free solution (0.6 mL) containing 6 mg of pegfilgrastim (10 mg/mL) in a single-dose prefilled syringe with a 27 gauge, ½ inch needle with an UltraSafe Plus™ Passive Needle Guard, to reduce the risk of accidental needle sticks for users.
PrFilra® is currently authorized for sale by Health Canada in the form of 0.5 mL single-use pre-filled syringe, without preservatives and also equipped with an UltraSafe Plus™ passive needle protection device, containing 300 mcg of filgrastim (600 mcg/mL). The 0.8 mL single-use pre-filled syringe, without preservatives and equipped with an UltraSafe Plus™ passive needle protection device, contain 480 mcg of filgrastim (600 mcg/mL). PrFilra® is distributed in boxes of 1 and in boxes of 10 syringes.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!